Profile of Sinobioway Biomedicine
Shandong Sinobioway Biomedicine Corp., Ltd. (hereafter referred to as “Sinobioway Biomedicine” or “the company”) is the core backbone company affiliated to Sinobioway Group and the only existing listed company and operating platform of capital of Sinobioway (stock code: sz002581). It was formed through the alliance and major assets restructuring with Sinobioway Biomedicine Co., Ltd. in June, 2015, and was renamed on October 19th 2015. The company has a registered capital of 659.736 million yuan.
Sinobioway Biomedicine has three manufacturing bases in Zibo (Shandong Province), Xiamen, (Fujian Province) and Tianjin. In addition to the headquarters in Zibo, it has the core assets of the wholly-owned subsidiary of Sinobioway Bio, holding sub-subsidiary company Tianjin Hualida Bioengineering Co., Ltd. (Hualida), Beijing Weiming Xida Biotech Co., Ltd. (Sinobioway Xida), joint-stock sub-subsidiary Sinovac Biotech Co., Ltd. (Sinovac).
The Zibo headquarters (formerly known as Wanchang Science & Technology) is the largest manufacturer and supplier of trimethyl orthoformate and triethyl orthoformate in China. A state-level high-tech enterprise and a key high-tech enterprise of the National Torch Program, it was founded in January, 2000 and was listed on the SMEs board of Shenzhen Stock Exchange in May, 2011, the first listed company in Zhangdian District, Zibo City. It focuses on the comprehensive utilization of hydrocyanic acid gas produced by the acrylonitrile unit. Through independent innovation, it has developed the new process of “exhaust hydrocyanic acid method” in the production of trimethyl orthoformate and triethyl orthoformate, which is a new technology of circular economy and the comprehensive utilization of resources. It has such research and development institutions as technical centers at the provincial level, provincial academician workstation, and provincial engineering technology research center for hydrocyanic acid application. By far it has won 14 state authorized invention patents, 6 patents for utility models, one pending patent and over 30 proprietary technologies. In terms of productivity, its leading product, trimethyl orthoformate, has an annual capacity of 12,000 ton, triethyl orthoformate 10,000 ton, trimethyl orthoacetate 5,000 ton, phosphorous acid 8,000 ton, ethyl formate 500 ton, and absolute ethanol 20,000 ton. The products are sold to over twenty provinces at home and exported to over twenty counties and regions in Europe and the America. In particular, it is the excellent supplier for Fortune Global 500 firms such as Syngenta, Bayer, Pfizer, and DSM; at home, it has established long-term strategic partnership with such famous domestic enterprises as Zhejiang NHU, Xinhua Pharmaceutical, and Zhejiang Medicine.
Sinobioway Bio, its wholly-owned subsidiary, is ranked top 30 among China’s biological pharmaceutical companies. A state-level high-tech enterprise located within Xiamen Biopark, it was founded in December, 1998. It has National Post-Doctoral Research Center, and a China Lab co-established with the European Brain Research Institute (EBRI). The leading product “NOBEX”, murine nerve growth factor for injection, is the first nerve growth factor drug approved for clinical use in the world, the first industrialized achievement of the Nobel Prize in Physiology or Medicine initiated by Chinese, and the first brand of China’s nerve growth factor market.
Hualida Bio, the holding sub-subsidiary, is among the pioneers in the industrialization of genetic engineering pharmaceuticals in China. It was founded in 1992 located in Tianjin Economic Technology Development Area (TEDA). Its leading products include “Anferon” (human recombinant interferon alpha 2 b injection) and “Jaferon” (Human recombinant interferon alpha 2 b sprays). It is equipped with domestically the largest production line for freeze-dried interferon powder injection and the most advanced production line for pre-filled glass syringe injection, with interferon produced at 20 million pieces per year.
Sinovac, the joint stock company, is China’s only professional vaccine company listed in North America. In 2001 after its incorporation, it successively launched “Healive”, China’s first inactivated hepatitis A vaccine, “Bilive”, China’s first and the world’s second combined hepatitis A and B Vaccine, “Panflu”, China’s first pandemic influenza vaccine developed synchronously with the world (human bird flu vaccine), “Anflu”, the only preservative-free domestic split influenza virus vaccine, and “Panflu.1”, the first Type A H1N1 influenza vaccine, ect..
Following Sinobioway’s development thought of “initiating a market with a product; develop a company with a market, establish a base with a company and promote an industry with a base”, Sinobioway Biomedicine, with its three manufacturing bases, shall focus on development positioning based on its own advantages and accelerate its development thorough the integration of advantageous resources. It endeavors to achieve outstanding business performances so as to reward its shareholders, investors, staff and the society!